FDA Expands Market Access, Authorizes New ENDS Products
FDA Expands Market Access, Authorizes New ENDS Products
http://www.fda.gov/news-events/press-announcements/fda-expands-market-access-authorizes-new-ends-products
FDA Expands Market Access, Authorizes New ENDS Products
http://www.fda.gov/news-events/press-announcements/fda-expands-market-access-authorizes-new-ends-products
Oscar Reyes
4 May 2026
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
http://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia
http://www.fda.gov/news-events/press-announcements/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia
Cristina Mitchell
30 Apr 2026
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
http://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
Oscar Reyes
29 Apr 2026